PharmiWeb.com - Global Pharma News & Resources
PharmiWeb Today Story
Almirall and Iktos announce research collaboration in Artificial Intelligence for new drug design
  • Generative modelling artificial intelligence (AI) technology will be used to optimise advanced compounds, to speed up the identification of promising drug candidates for an undisclosed Almirall drug discovery program.
  • This tackles one of the key challenges in drug design: rapid identification of molecules which simultaneously satisfy multiple bioactivity and drug-like criteria for clinical testing.
  • Through this collaboration, Almirall will leverage Iktos’s AI precision and agility to truly make a difference in patients' lives.

Almirall, S.A. (ALM), a leading skin-health focused global pharmaceutical company, and Iktos, a company specialized in Artificial Intelligence for novel drug design, today announced a collaboration agreement in Artificial Intelligence (AI) , where Iktos generative modelling AI technology will be used to design novel optimized compounds, to speed up the identification of promising drug candidates for an undisclosed Almirall drug discovery program(s).

Iktos’ AI technology, based on deep generative models, helps bring speed and efficiency to the drug discovery process, by automatically designing virtual novel molecules that have the desirable characteristics of a novel drug candidate. This tackles one of the key challenges in drug design: rapid and iterative identification of molecules which simultaneously validate multiple bioactive attributes and drug-like criteria for clinical testing.

This partnership is an example of how we intend to explore the enormous possibilities offered by technology to find new molecules and to speed up clinical developmen…

Read More...
Almirall and Iktos announce research collaboration in Artificial Intelligence for new drug design

Articles